Skip to main content

Table 2 Clinic characteristics of screening cohort

From: Urinary small extracellular vesicles derived CCL21 mRNA as biomarker linked with pathogenesis for diabetic nephropathy

  Healthy control (n  =  4) T2DM (n  =  4) DN (n  =  4)
Males 2 (50%) 2 (50%) 2 (50%)
Age (years) 31 (25–38) 55 (49–59) 51 (47–53)
BMI (kg/m2) 23.67 (21.68–26.31) 25.50 (20.57–29.73) 25.96 (20.02–32.12)
Total cholesterol (g/L) 5.08 (2.93–6.96) 4.66 (4.22–5.15)
Triglyceride (mg/dL) 2.14 (1.17–3.34) 2.00 (1.68–2.20)
BUN (mmol/L) 4.9 (4.1–5.5) 7.1 (5.6–8.3) 12.4 (7.5–16.4)**#
SCr (umol/L) 70.5 (61.3–79.3) 81.3 (69.8–91.5) 161.5 (105.5–219.5)*#
UA (umol/L) 310 (294–324) 308 (269–365) 333 (308–375)
Plasma albumin (g/L) 48 (45–51) 42 (38–45) 31 (25–36)**#
eGFR (ml/min/1.73m2) 94 (81.3–112.5) 90 (81.3–101.3) 57.8 (48.9–67.4)**#
Urinary ACR (mg/g) 2.4 (0–8.9) 55 (5–150) 579 (208–707)**##
  1. eGFR has been calculated using the CKD-EPI Creatinine formula (ml/s per 1.73 m2). Values are expressed as median (IQR) (Mann–Whitney U test, *p  <  0.05, **p  <  0.01 compared with healthy controls; #p  <  0.05, ##p  <  0.01 compared with T2DM)
  2. BMI body mass index; BUN blood urea nitrogen; SCr serum creatinine; UA uric acid; eGFR estimated glomerular filtration rate